The escalating prevalence of obesity has been linked to substantial increases in both metabolic and cardiovascular disease. Nevertheless, the direct effects of obesity on cardiovascular health and function require further exploration.
1 In 2014, nearly 1.9 billion adults worldwide were overweight, and more than 600 million were obese. 1, 2 Obesity is an independent risk factor for several chronic noncommunicable diseases (NCDs) including diabetes, cancer, and cardiovascular disease (CVD), the lattermost which includes heart failure (HF). This cluster of NCDs collectively represents the major causes of death worldwide. [1] [2] [3] [4] [5] [6] In this context, there clearly appears to be a cause and effect relationship between obesity and the increased risk for development of one or more NCDs.
The interplay between obesity and HF is complex. Paradoxically, although obesity increases the risk of HF, once a diagnosis is confirmed, patients with HF who are also obese have a better prognosis compared with their leaner counterparts. This phenomenon has been termed the obesity paradox. [6] [7] [8] [9] In this review, we describe the role of obesity in the development of HF and the possible mechanism(s) through which obesity may exert protective effects in HF. We also discuss the role of diet and systemic inflammation and their involvement in cardiac dysfunction as well as potential body compositione, diet-, and systemic inflammationetargeted therapeutic strategies.
MATERIAL AND METHODS
For this critical review, we identified articles by searching original studies, review articles, and editorials published in peer-reviewed journals indexed in PubMed and Google Scholar between January 1, 1960 , and March 30, 2016 . The comprehensive electronic literature search included the use of key words and their combination: obesity, heart failure, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, obesity and heart failure, obesity paradox, obesity paradox in heart failure, body composition, body composition and heart failure, lean mass, weight loss and heart failure, diet and heart failure, diet and cardiac function, inflammation and heart failure, sarcopenia, sarcopenia and heart failure, sarcopenic obesity, sarcopenic obesity and heart failure, and inflammation and heart failure. Of more than 1000 articles found, 139 were considered to be relevant to the scope of this critical review. The search was restricted to articles published in English. The reference lists of the chosen studies were also reviewed to identify potential additional pertinent articles.
OBESITY AND HF: DEFINITIONS AND EPIDEMIOLOGY
The World Health Organization defines obesity and overweight as "an abnormal or excessive fat accumulation.to the extent that health may be impaired." 1 However, universal cutoffs of body fat to diagnose overweight and obesity have not been established. Therefore, overweight and obesity are usually diagnosed in individuals with a BMI of 25 kg/m 2 or higher and a BMI of 30 kg/m 2 or higher, respectively. Visceral obesity, often considered a better tool than BMI to determine a more complete cardiometabolic risk, 10,11 is defined as a waist circumference of more than 102 cm in males and more than 88 cm in females, although race-related cutoffs have been proposed. 12 Heart failure is "a complex clinical syndrome that results from any structural or functional impairment of ventricular filling and/or ejection of blood." 13 Heart failure affects about 38 million people worldwide, almost 6 million in the United States alone with nearly 915,000 new cases every year.
14 Moreover, it is the most common reason for hospital admissions in patients aged 65 years or older. 14, 15 Although the survival rate in patients with HF has improved in recent history, the death rate remains very high: more than 30% of patients die within 5 years of an HF diagnosis. 14, 15 Approximately half of the patients with HF have a reduced left ventricular (LV) ejection fraction (LVEF) or systolic dysfunction (ie, HF with reduced ejection fraction [HFrEF] ), while the remaining half present with preserved LVEF (ie, HF with preserved ejection fraction [HFpEF]), 13, 16 usually characterized by the presence of diastolic dysfunction, also known as diastolic HF. These 2 forms of HF have very different pathophysiologic mechanisms, which are highlighted by the fact that beneficial therapeutic strategies in HFrEF have failed to improve outcomes in HFpEF. [13] [14] [15] [16] [17] [18] For instance, in HFrEF, the renin-angiotensin-aldosterone system represents a target for several drugs proven to reduce mortality and complications. 13, 19 However, similar pharmacological approaches targeting the renin-angiotensinaldosterone system failed to produce beneficial effects in patients with HFpEF.
Despite sharing very similar signs and symptoms, such as fluid retention, shortness of breath, and exercise intolerance, HFpEF and HFrEF differ not only on the differences in LVEF but also in epidemiology and clinical characteristics. 13, [15] [16] [17] [18] Heart failure with preserved ejection fraction is more prevalent in women and it more characteristically associates with obesity; up to 85% of patients with HFpEF are in fact obese, 6, 20 while in HFrEF, obesity prevalence is usually lower than 50%. 21, 22 As mentioned previously, obesity increases the risk of HF 4, 5, 23 ( Figure 1 ). Overall, approximately 38% of patients with HF are obese. 20 The mechanism(s) behind the association of obesity with HF, particularly with HFpEF, are not well known, although several plausible
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hypotheses have been proposed. [6] [7] [8] [9] [24] [25] [26] [27] In the following sections, we will focus our attention on the potential contribution of body composition to the development of HF in obese individuals and how body composition, rather than BMI, may be a better predictor of outcomes once HF has been diagnosed.
OBESITY-INDUCED HEMODYNAMIC AND STRUCTURAL CHANGES
The pathophysiology of HF is very complex. Ventricular remodeling resulting in hemodynamic and structural changes, neurohormonal system activation, systemic inflammation, and abnormalities in calcium fluxes are involved in the development and progression of the disease. 16 In particular, hemodynamic abnormalities and structural cardiac changes have been reported in obese patients [6] [7] [8] [9] [24] [25] [26] [27] (Figure 2 ). The hemodynamic changes include increased central blood volume and stroke volume and ultimately increased cardiac output [6] [7] [8] [9] [24] [25] [26] [27] [28] [29] [30] proportional to the degree of obesity but not body surface area. 31 The increased blood volume seems to result from the increased amount of lean mass seen in most obese patients. 8, 9, 24, 31 In fact, although obesity by definition is characterized by a higher amount of fat mass, 1 the classic obesity phenotype also presents with a preserved or increased amount of lean mass. [7] [8] [9] 24, 32 The main component of lean mass is skeletal muscle. 33, 34 Although the terms lean mass and skeletal muscle mass are often used interchangeably, the correct definition of lean mass is the sum of bone mineral mass, skeletal muscle mass, and residual mass. 34 Clinically, an accurate measurement of skeletal muscle mass is very challenging, and therefore, it is often estimated from the measurement of lean mass.
The fact that the blood flow requirement for skeletal muscle mass is significantly higher than that for fat mass is particularly relevant. 35 Specifically, higher amounts of skeletal muscle mass, and not fat mass, with the associated increase in blood flow and central blood volume seem to be a main contributors to the increased stroke volume seen in the obese HF phenotype. Because heart rate is either not augmented or, at a maximum, just moderately increased due to the sympathetic system activation in obese patients, 6 ,9,24 the increased cardiac output appears to mainly result from the increased stroke volume. The sustained increase in cardiac output due to increased preload, however, leads to an initial LV dilatation followed by a compensatory hypertrophic response evident at both a cellular and organ level. 20, 32 In fact, LV hypertrophy is often present in obese patients. [7] [8] [9] 31, [36] [37] [38] [39] [40] [41] Interestingly, although impairment in diastolic function and increased filling pressures were at first considered to be the result of the increased LV mass, it has been reported that obese patients may present with diastolic dysfunction without LV hypertrophy, 42, 43 suggesting potential alternative mechanisms involved. Indeed, LV hypertrophy may even be protective by reducing wall stress. Obese patients with HFpEF have increased relative wall thickness and reduction of the size of cardiac cavities 17, [43] [44] [45] [46] even in the absence of increased LV mass, 6, 41, [47] [48] [49] [50] which is referred to as LV concentric remodeling and appears to carry similar, if not worse, prognostic information (ie, higher cardiovascular complications or death) in patients with HF. 51, 52 Moreover, the increase in BMI in obese patients positively correlates with cardiac output as well as with LV end-diastolic pressure, right atrial pressure, and pulmonary capillary wedge pressure. 6, [53] [54] [55] These hemodynamic and structural changes may represent compensatory mechanisms that may, however, lead to detrimental 
OBESITY, DIET, AND HFPEF
A form of HF that has been increasing in incidence in the past few decades is characterized by impaired diastolic function associated with preserved LVEF and no major coronary artery, valvular, or arrhythmic disease. This syndrome is referred to as HFpEF or diastolic HF. 17, 20, 56 Most patients with HFpEF are obese and have evidence of metabolic derangements such as insulin resistance and diabetes. 17, 56 It is therefore conceivable that obesity and diastolic dysfunction are causally linked.
The mechanisms by which obesity may induce diastolic dysfunction and therefore increase the risk of HFpEF are still unclear. Several hypotheses have been proposed including a potential involvement of direct cardiodepressant factors produced by the adipose tissue. 18, 57 The adipose tissue is an active endocrine organ able to synthesize a number of hormones or active molecules called adipokines. [58] [59] [60] In particular, the adipose tissue produces proinflammatory cytokines such as interleukin (IL) 1b, tumor necrosis factor a, Proposed mechanisms driving obesity to heart failure (HF) and to the obesity paradox once HF is diagnosed. The dark blue arrows indicate the potential detrimental effects of body composition components (fat mass and lean mass) on cardiac function and eventually HF development. The light blue arrows indicate the potential mechanisms by which body composition improves cardiorespiratory fitness (CRF). IL ¼ interleukin; LV ¼ left ventricular; LVH ¼ LV hypertrophy; SVR ¼ systemic vascular resistance; TNF-a ¼ tumor necrosis factor a.
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and IL-18, 59 which induce diastolic dysfunction in preclinical animal models. 59, 61, 62 In support of these hypotheses, pilot studies with targeted anti-inflammatory treatment have reported promising results in HF, including HFpEF. 61, 63, 64 In these pilot studies, short-term IL-1 blockade strategies with a human recombinant IL-1 receptor antagonist improved cardiorespiratory fitness (CRF) in patients with HFrEF 63 and HFpEF, 64 and both studies found a significant increase of peak oxygen consumption ( _ VO 2 ), an independent predictor of outcomes in HF.
Furthermore, obesity is considered the result of an unhealthy diet. Recent studies have found that a high-sugar (30% of total calories) and highesaturated fat (12.8% of total calories) diet resembling a typical diet of Western countries (Western diet) can directly impair cardiac diastolic and systolic function in experimental animals, 65, 66 providing a potential link between diet-induced inflammation and cardiac dysfunction (Figure 2) . Moreover, returning to a healthy diet low in saturated fat and sugar induced significant improvements in cardiac function, highlighting a major ability of the diet to modulate both systolic and diastolic function. [65] [66] [67] [68] [69] Sugars and saturated fat can activate proinflammatory pathways; specifically, they can induce the synthesis and activation of the macromolecular complex Nod-like receptor pyrin domainecontaining protein 3 inflammasome [70] [71] [72] responsible for the production of IL-1 and IL-18, cytokines with wellknown cardiodepressant properties. A diet low in sugars and saturated fat could perhaps improve cardiac function and CRF by limiting the synthesis and activation of the macromolecular complex Nod-like receptor pyrin domainecontaining protein 3 inflammasome and of cytokines IL-1 and IL-18.
THE OBESITY PARADOX IN HF
Although the risk of HF increases with BMI, patients with HFrEF who are overweight or obese commonly have better outcomes than those who are normal weight or underweight, [7] [8] [9] [24] [25] [26] [73] [74] [75] [76] [77] [78] [79] even when high BMI manifests several years before an HF diagnosis. 80 A secondary analysis of the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) included 31 studies, both randomized controlled trials and observational studies. This meta-analysis revealed a relationship between BMI and mortality in both HFrEF and HFpEF, with the lowest mortality rate seen in those with class 1 obesity 81 ( Figure 3) . A later meta-analysis including about 22,000 patients who had chronic HF (HFrEF and HFpEF) with a mean follow-up of almost 3 years reported a similar outcome; overweight patients presented with the lowest total and CV mortality rate compared with those who were normal weight, while underweight patients had the highest mortality rate and patients with class 2 and higher obesity had an intermediate prognosis with lower total and CV mortality despite increased HF hospitalizations. 82 Recently, it has also been observed that the obesity paradox is particularly relevant in women with advanced HF. 83 Based on these data, researchers have started to explore potential mechanisms for the obesity paradox. A plausible explanation is related to the inaccuracy of the BMI in characterizing the severity of obesity. [84] [85] [86] [87] [88] [89] [90] The World Health Organization definitions of obesity imply that every individual with a BMI of 25 kg/m 2 or higher, and even more so when BMI is 30 kg/m 2 or higher, have increased fat mass. 1 However, this implication is not necessarily true. Body mass index has in fact several limitations, and as such it should be considered more of a measurement of heaviness than body composition. Patients with increased BMI may not necessarily have increased fat mass (eg, athletes), 91, 92 while having a normal BMI (!18.5 kg/m 2 and <25 kg/m 2 ) does not preclude an individual from having increased fat mass and thus increased metabolic and CVD risk. 93 Thus, an accurate measurement of body composition, rather than BMI, that defines body weight components (ie, fat mass, fat-free mass, lean mass) likely plays a crucial role in the development and progression of CVD, including HF. Nevertheless, at least at a population level, BMI has predicted CVD and all-cause survival, 94, 95 and more specific fat distribution measures, such as waist circumference and waist to hip ratio, do not outperform BMI in predicting the incidence of HF. 96 
SKELETAL MUSCLE MASS AND ITS PROTECTIVE EFFECTS IN HF
Although we have described the potential involvement of body composition components in the initial cardiac abnormalities leading to increased HF risk, increased skeletal muscle mass seen in obese individuals may actually also exert protective effects related to better outcomes in HF.
With respect to HF pathophysiology, characterized by reduced or inadequate cardiac output and increased systemic vascular resistance, 13 it is plausible that obese individuals with preserved skeletal muscle mass have a better prognosis secondary to increased stroke volume and thus cardiac output (ie, improved tissue perfusion) compared with their counterparts who have reduced lean mass and lower stroke volume and cardiac output. Moreover, obese patients tend to have lower systemic vascular resistance, especially those who are normotensive. [6] [7] [8] [9] 24, 35 Reduction in the afterload results in improved forward flow and cardiac output. However, whether systemic vascular resistance is reduced only in obese patients with preserved or increased skeletal muscle mass or if this also occurs in patients with reduced skeletal muscle mass requires further investigation.
OBESITY PHENOTYPES AND OUTCOMES
Hypothesizing a major protective role of skeletal muscle mass in patients with HF is consistent with what has already been observed in other disease states, such as diabetes and cancer, in which reduced lean mass is associated with poor outcomes and metabolic abnormalities, a muscle deficiency condition known as sarcopenia. 97 When sarcopenia is paralleled by an increase in fat mass (obesity), it is termed sarcopenic obesity, bringing together body composition abnormalities of both conditions, sarcopenia and obesity. 98, 99 Sarcopenic obesity is becoming extremely prevalent and is related to poor outcomes in a number of chronic diseases. A recent meta-analysis of 40 HFrEF <22. FIGURE 3. Total mortality stratified by body mass index (BMI) and heart failure (HF). Patients with HF and higher BMI had a lower mortality rate than those with a lower BMI. Heart failure is categorized as HF with reduced ejection fraction (HFrEF) or HF with preserved ejection fraction (HFpEF). Adapted from Int J Obes (Lond), 81 with permission from Nature Publishing Group.
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prospective cohort studies including more than 35,000 patients found that sarcopenic obese patients had a 24% increased risk for all-cause mortality compared with those who were nonsarcopenic and obese. Another analysis highlighted the importance of identifying patients with sarcopenic obesity as early as possible to begin interventions directed toward improving body composition, with the goal of improving outcomes. 100 A recent study reported that sarcopenia was associated with lower muscle strength and exercise capacity and worse quality of life in patients with HFpEF. 101 However, whether these results translate into similar long-term outcomes in HF, as seen in non-HF patients, requires further study.
OBESITY, BODY COMPOSITION, AND CRF
Lean mass and skeletal muscle mass, particularly appendicular muscle mass (ie, the amount of skeletal muscle mass in the arms and in the legs) has been suggested to be a major determinant of CRF in patients with HF. 102 Peak oxygen consumption assessed by a cardiopulmonary exercise test is the criterion standard assessment of CRF and is an independent predictor of outcomes in HF. The minute ventilation/carbon dioxide production ( _ VE/ _ VCO 2 ) slope, which quantifies ventilatory efficiency, is also a primary predictor of outcomes in patients with HF. 103, 104 In fact, a number of investigations have indicated that the _ VE/ _ VCO 2 slope is a stronger independent prognostic marker than peak _ VO 2 , although both measures assessed in combination improve prognostic resolution. 105 107 Obesity contributes to exercise intolerance, particularly in patients with HFpEF, and not necessarily by directly affecting cardiac function. 108 Obese patients seem to have a lower peak _ VO 2 than leaner individuals, 109, 110 however, only if the peak _ VO 2 is corrected for body weight, without adjusting for body composition compartments. 102, 111 When corrected for lean mass or skeletal muscle mass, at least in patients with HFrEF, these differences do not persist. 102, 112 Moreover, it has been suggested that correcting peak _ VO 2 for lean mass or skeletal muscle mass, rather than body weight, may improve risk stratification in patients with HF. [6] [7] [8] [9] 24, 102, 111 In particular, appendicular muscle mass positively correlates with peak _ VO 2 in noncachectic patients with HFrEF. 102 Lean mass can be assessed easily and accurately by dual-energy x-ray absorptiometry that allows for the estimation of appendicular muscle mass. 34 Based on the previous findings, it would be reasonable to assume that higher amounts of lean mass exert protective effects in patients with HF. Although most of the studies on obesity, body composition, and HF have been performed in patients with HFrEF, a retrospective analysis of more than 47,000 patients with HFpEF reported a significant protective effect of lean mass in predicting all-cause mortality, regardless of BMI or fat mass. 113 An initial analysis of this study 113 suggested that higher BMI and fat mass were FIGURE 4. Hypothetical relationship between obesity phenotypes, cardiac function, and cardiorespiratory fitness in patients with heart failure. The figure highlights the proposed major role of body composition, obesity phenotypes, and lean mass in the development and progression of cardiac dysfunction and cardiorespiratory fitness abnormalities. BMI ¼ body mass index. Adapted from EC Cardiol.
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associated with lower mortality. When adjusted for lean mass index (kg/m 2 ), however, these associations were not supported, therefore suggesting that the protective component of high body weight and BMI was not fat mass but lean mass. This study has some limitations characteristic of most studies assessing body composition in HF, mainly because of the technique used to determine body composition. A skinfold caliper was used to assess fat mass with a consequent subtraction from the total body weight to calculate the estimated amount of lean mass, or the fat mass was calculated with a validated predictive equation taking into account body weight and BMI without an actual assessment of body composition. We can, however, speculate that sarcopenic obese patients, characterized by increased fat mass and reduced appendicular lean mass, would have worse cardiac function and CRF than obese patients with a preserved or increased amount of appendicular lean mass, independent of BMI ( Figure 4) . 57, [114] [115] [116] [117] [118] It has been also proposed that the quality of lean mass may play an important role. In fact, despite a similar amount of lean mass, elderly patients with HF have reduced skeletal muscle oxidative function compared with age-matched healthy controls. 116 Moreover, sarcopenia and sarcopenic obesity are characterized by low-grade chronic systemic inflammation. [119] [120] [121] As described earlier, systemic inflammation (ie, IL-1, IL-18) negatively and directly affects cardiac function and exercise capacity in patients with HF. 61, 63, 64 Therefore, it is plausible to hypothesize that increased systemic inflammation in individuals with sarcopenia and sarcopenic obesity contributes to worsening prognosis. It is also possible that increased low-grade systemic inflammation contributes to the progressive loss of lean mass, which in turn increases even the proinflammatory state further.
CRF AND THE OBESITY PARADOX
It is well known that CRF represents an important prognostic factor in patients with HF.
Studies have found that the obesity paradox does not persist in patients with HF who have a relatively preserved CRF level, defined by a peak _ VO 2 of 14 mL•kg
À1
•min À1 or higher ( Figure 5 ). 122, 123 When patients are stratified by CRF level using a peak _ VO 2 cutoff of 14 mL•kg À1 •min
, the protective effects of high BMI disappear, highlighting the more prominent role of CRF, rather than BMI, in defining HF prognosis. Those patients with impaired but relatively higher peak _ VO 2 and a higher degree of lean mass and CRF tend to have a better clinical trajectory, regardless of BMI. Similar findings have been reported in metabolically healthy obesity, which is defined as obesity according to BMI criteria but without metabolic syndrome characteristics such as glucose abnormalities and hypertension. 124, 125 WEIGHT LOSS IN HF Intentional weight loss, through a combination of diet and exercise, is often considered the best therapeutic approach for patients with obesity and related comorbidities, particularly metabolic diseases such as type 2 diabetes, in which weight loss is associated with improvements in glucose control and a reduction in CVD risk. 126 Whether weight loss is also beneficial in obese patients with HF is unclear at this time. A recent study reported that caloric restriction and/or exercise interventions for 20 weeks induced favorable effects on body weight, body composition, and CRF in patients with HFpEF, 127 suggesting beneficial effects of intentional weight loss. Additional evidence suggests that intentional weight loss resulting from diet, physical activity, bariatric surgical interventions, or a combination thereof may positively affect hemodynamics and cardiac morphology, independent of age, sex, BMI, and comorbidities. 128 Long-term data documenting improved survival in patients with HF following weight loss are, however, still lacking. Weight loss in HF is often considered the result of a cachectic process and is related to poor outcomes. 129, 130 Pocock et al 131 assessed the effects of 6-month body weight changes 33 months after baseline assessment in HF. Interestingly, the degree of weight loss was positively associated with increased mortality, regardless of initial body weight or BMI, even in obese individuals. This study, however, did not assess whether weight loss was intentional or unintentional. Moreover, a body composition assessment was not performed to assess whether weight loss was related to a reduction of fat mass and, perhaps more importantly, loss of lean mass that is expected in cachectic patients. Rapid weight loss can, in fact, be associated with a reduction in lean mass. 132, 133 Because lean mass has been hypothesized to exert protective effects in HF, its reduction could increase the risk for development of sarcopenia and sarcopenic obesity, paradoxically increasing mortality risk. Large randomized controlled trials assessing the direct effect of intentional weight loss should be encouraged, accurately assessing body composition to determine whether the intervention induced changes in fat mass and lean mass rather than just focusing on body weight. Because of the lack of strong evidence, however, major guidelines do not recommend weight loss in HF but rather suggest avoiding unintentional weight loss. 16 Although large studies are lacking, it may be reasonable to hypothesize that intentional weight lossdpreferably of fat mass while preserving or increasing lean massdcould exert beneficial effects. However, it should be recognized that one of Lifestyle modification FIGURE 6. Proposed nonpharmacological therapy for patients with heart failure. In addition to standard of care, we hypothesize that a diet with low proinflammatory effects (low sugars and low saturated fat) and increased resistance training, potentially increasing the amount of lean mass, will improve cardiorespiratory fitness and perhaps prognosis in patients with heart failure. ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker.
the reasons why obesity may be associated with better outcomes in HF may be the correlation of increased body fat with greater muscular strength. 134, 135 Because the effects of weight loss in HF are currently unclear, interventions should focus on improving CRF in obese patients with HF, regardless of the effect on body weight. Exercise training (ET) and increased physical activity have indeed produced beneficial effects, and better CRF correlates with better outcomes, regardless of BMI. 136 Additionally, physical activity, ET, and higher CRF have been reported to reduce the development of HF in the first place. 137 Although aerobic-type exercise is usually recommended as the primary approach, it is unknown whether this form of training is superior to resistance ET. Based on the knowledge that lean mass, particularly appendicular lean mass, may exert protective effects, resistance ET aimed to increase muscle mass and strength may be helpful ( Figure 6 ). 134, 138 Additionally, this strategy may also prove helpful for obese patients with very advanced HF when LV assist devices are being used, especially as a potential bridge to heart transplant. 139 
CONCLUSION
High BMI represents a risk factor for HF but also exerts protective effects in certain circumstances. The exact mechanisms related to the increased risk of HF and the associated protective effects once HF is diagnosed are not well known. However, we believe that lean mass plays a major role in outcome differences seen in the HF population. As such, a better risk stratification of HF patients based on body composition rather than just on BMI may be encouraged to identify patients at higher risk (ie, identifying those with sarcopenia and sarcopenic obesity) in whom strategic interventions aimed at preserving or increasing lean mass may be clinically beneficial. In addition to standard medical treatment in patients with HF, a major focus on improving CRF with ET, including resistance ET to increase muscle mass and strength, appendicular lean mass, and its functionality, is recommended.
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